New York State Common Retirement Fund Enanta Pharmaceuticals Inc Transaction History

New York State Common Retirement Fund

$74.9 Billion
Q3 2025

A detailed history of New York State Common Retirement Fund transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, New York State Common Retirement Fund holds 7,771 shares of ENTA stock, worth $93,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,771

Previous 7,771 -0.0%

Holding current value

$93,718

Previous $58,000 60.34%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$11.43 - $17.02 $468 - $697	41 Added 0.53%	7,771 $101,000
Q1 2024 Oct 08, 2025	SELL	$10.08 - $17.46 $413 - $715	-41 Reduced 0.53%	7,730 $134,000
Q1 2024 May 07, 2024	SELL	$10.08 - $17.46 $423 - $733	-42 Reduced 0.54%	7,730 $135,000
Q4 2023 Oct 08, 2025	BUY	$8.18 - $10.78 $8 - $10	1 Added 0.01%	7,772 $73,000
Q4 2023 Feb 01, 2024	SELL	$8.18 - $10.78 $19,141 - $25,225	-2,340 Reduced 23.14%	7,772 $73,000

Q3 2023 Oct 08, 2025	BUY	$11.09 - $22.13 $25,961 - $51,806	2,341 Added 30.12%	10,112 $112,000
Q3 2023 Nov 07, 2023	BUY	$11.09 - $22.13 $621 - $1,239	56 Added 0.56%	10,112 $113,000
Q2 2023 Oct 08, 2025	BUY	$20.68 - $39.85 $47,253 - $91,057	2,285 Added 29.4%	10,056 $215,000
Q2 2023 Aug 07, 2023	BUY	$20.68 - $39.85 $3,226 - $6,216	156 Added 1.58%	10,056 $215,000
Q1 2023 Oct 08, 2025	SELL	$38.82 - $54.59 $186,336 - $262,032	-4,800 Reduced 32.65%	9,900 $400,000
Q1 2023 May 02, 2023	SELL	$38.82 - $54.59 $186,336 - $262,032	-4,800 Reduced 32.65%	9,900 $400,000
Q4 2022 Oct 08, 2025	BUY	$40.77 - $53.73 $282,495 - $372,295	6,929 Added 89.16%	14,700 $683,000
Q3 2022 Nov 08, 2022	SELL	$48.29 - $71.27 $241 - $356	-5 Reduced 0.03%	14,700 $762,000
Q2 2022 Aug 04, 2022	SELL	$38.13 - $76.93 $184,396 - $372,033	-4,836 Reduced 24.75%	14,705 $695,000
Q1 2022 May 05, 2022	SELL	$56.06 - $74.11 $637,121 - $842,260	-11,365 Reduced 36.77%	19,541 $1.39 Million
Q4 2021 Feb 02, 2022	SELL	$60.19 - $97.37 $26,965 - $43,621	-448 Reduced 1.43%	30,906 $2.31 Million
Q3 2021 Nov 02, 2021	SELL	$41.02 - $58.65 $96,520 - $138,003	-2,353 Reduced 6.98%	31,354 $1.78 Million
Q2 2021 Aug 02, 2021	SELL	$43.76 - $53.11 $183,398 - $222,584	-4,191 Reduced 11.06%	33,707 $1.48 Million
Q4 2020 Feb 08, 2021	BUY	$41.16 - $47.47 $269,598 - $310,928	6,550 Added 20.89%	37,898 $1.6 Million
Q2 2020 Aug 07, 2020	BUY	$46.37 - $57.58 $396,463 - $492,309	8,550 Added 37.5%	31,348 $1.57 Million
Q1 2020 May 06, 2020	BUY	$40.22 - $62.0 $4,022 - $6,200	100 Added 0.44%	22,798 $1.17 Million
Q4 2019 Feb 05, 2020	SELL	$57.95 - $66.61 $214,415 - $246,457	-3,700 Reduced 14.02%	22,698 $1.4 Million
Q3 2019 Nov 07, 2019	SELL	$60.08 - $88.17 $465,559 - $683,229	-7,749 Reduced 22.69%	26,398 $1.59 Million
Q2 2019 Aug 09, 2019	SELL	$81.3 - $97.35 $24,390 - $29,205	-300 Reduced 0.87%	34,147 $2.88 Million
Q1 2019 May 08, 2019	BUY	$69.08 - $105.66 $13,816 - $21,132	200 Added 0.58%	34,447 $3.29 Million
Q4 2018 Feb 08, 2019	SELL	$65.41 - $84.65 $234,821 - $303,893	-3,590 Reduced 9.49%	34,247 $2.43 Million
Q3 2018 Nov 07, 2018	SELL	$85.46 - $126.37 $191,601 - $283,321	-2,242 Reduced 5.59%	37,837 $3.23 Million
Q2 2018 Aug 10, 2018	BUY	$81.85 - $120.51 $516,146 - $759,936	6,306 Added 18.67%	40,079 $4.65 Million
Q1 2018 May 10, 2018	SELL	$57.91 - $92.15 $316,478 - $503,599	-5,465 Reduced 13.93%	33,773 $2.73 Million
Q4 2017 Feb 13, 2018	SELL	$45.65 - $59.37 $464,717 - $604,386	-10,180 Reduced 20.6%	39,238 $2.3 Million
Q3 2017 Nov 06, 2017	BUY	$37.91 - $46.8 $467,809 - $577,512	12,340 Added 33.28%	49,418 $2.31 Million
Q2 2017 Aug 11, 2017	BUY	N/A	37,078	37,078 $1.33 Million

Others Institutions Holding ENTA

# of Institutions

128

Shares Held

19.4M

Call Options Held

290K

Put Options Held

61.7K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $250M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.

Account

New York State Common Retirement Fund Enanta Pharmaceuticals Inc Transaction History